John A. Kemp

12.2k total citations · 1 hit paper
126 papers, 9.3k citations indexed

About

John A. Kemp is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Cognitive Neuroscience. According to data from OpenAlex, John A. Kemp has authored 126 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Cellular and Molecular Neuroscience, 78 papers in Molecular Biology and 25 papers in Cognitive Neuroscience. Recurrent topics in John A. Kemp's work include Neuroscience and Neuropharmacology Research (84 papers), Ion channel regulation and function (30 papers) and Receptor Mechanisms and Signaling (28 papers). John A. Kemp is often cited by papers focused on Neuroscience and Neuropharmacology Research (84 papers), Ion channel regulation and function (30 papers) and Receptor Mechanisms and Signaling (28 papers). John A. Kemp collaborates with scholars based in United States, United Kingdom and Switzerland. John A. Kemp's co-authors include James N.C. Kew, Adam M. Sillito, Alan C. Foster, Vincent Mutel, Ruth M. McKernan, Tony Priestley, Erik H.F. Wong, G.N. Woodruff, Gerhard Trube and Paul D. Leeson and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

John A. Kemp

124 papers receiving 9.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ionotropic and metabotropic glutamate receptor structure and pharmacology

2005 538 citations James N.C. Kew, John A. Kemp Psychopharmacology profile →

Peers

Countries citing papers authored by John A. Kemp

Since Specialization

Citations

This map shows the geographic impact of John A. Kemp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Kemp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Kemp more than expected).

Fields of papers citing papers by John A. Kemp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Kemp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Kemp. The network helps show where John A. Kemp may publish in the future.

Co-authorship network of co-authors of John A. Kemp

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Kemp. A scholar is included among the top collaborators of John A. Kemp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Kemp. John A. Kemp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Uremic toxins and inflammatory profile of patients with chronic kidney disease: A cross-sectional study involving non-dialysis, hemodialysis and peritoneal dialysis 2023 ·Clinical Nutrition ESPEN ·Bruna R. Paiva, L. Cardozo, Márcia Ribeiro, Marcelo Ribeiro‐Alves, Lia S. Nakao, (unknown), (unknown), Jessyca Sousa de Brito, John A. Kemp, (unknown), (unknown), (unknown), (unknown), Lívia Alvarenga, (unknown), Denise Mafra	0
2	Emergence of early alterations in network oscillations and functional connectivity in a tau seeding mouse model of Alzheimer’s disease pathology 2017 ·Scientific Reports ·A. Ahnaou, Diederik Moechars, (unknown), R. Biermans, Nikolay V. Manyakov, Astrid Bottelbergs, Cindy Wintmolders, Kristof Van Kolen, Tom Van de Casteele, John A. Kemp, Wilhelmus Drinkenburg	70
3	Ionotropic and metabotropic glutamate receptor structure and pharmacology breakdown → 2005 ·Psychopharmacology ·James N.C. Kew, John A. Kemp	538
4	Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent 2004 ·Neuropharmacology ·Guy A. Higgins, Theresa M. Ballard, James N.C. Kew, John Richards, John A. Kemp, Geo Adam, Thomas J. Woltering, Shigetada Nakanishi, Vincent Mutel	142
5	The Voltage-dependent Anion Channel Is the Target for a New Class of Inhibitors of the Mitochondrial Permeability Transition Pore 2003 ·Journal of Biological Chemistry ·Andrea M. Cesura, Emmanuel Pinard, Robert Schubenel, (unknown), Arno Friedlein, Hanno Langen, Peter Polčic, Michael Forte, Paolo Bernardi, John A. Kemp	86
6	Identification of Critical Residues in the Amino Terminal Domain of the Human NR2B Subunit Involved in the RO 25-6981 Binding Pocket 2003 ·Journal of Pharmacology and Experimental Therapeutics ·Pari Malherbe, Vincent Mutel, Clemens Broger, Florent Perin-Dureau, John A. Kemp, Jacques Neyton, Pierre Paoletti, James N.C. Kew	42
7	Differential regulation of synaptic transmission by mGlu2 and mGlu3 at the perforant path inputs to the dentate gyrus and CA1 revealed in mGlu2 -/- mice 2002 ·Neuropharmacology ·James N.C. Kew, (unknown), John A. Kemp, Vincent Mutel	46
8	Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischaemia 2002 ·European Journal of Neuroscience ·Guy A. Higgins, M Enderlin, (unknown), Marie Haman, Andrew J. Grottick, Marc A. Soriano, John Richards, John A. Kemp, R. Gill	37
9	Pharmacological Characterization of Ro 63-1908 (1-[2-(4-Hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a Novel Subtype-Selective N-Methyl-d-Aspartate Antagonist 2002 ·Journal of Pharmacology and Experimental Therapeutics ·R. Gill, Alexander Alanine, Anne Bourson, Bernd Büttelmann, G. Fischer, M. Heitz, James N.C. Kew, Bernard Levet‐Trafit, H.P. Lorez, Pari Malherbe, (unknown), Vincent Mutel, Emmanuel Pinard, S. Roever, Martine Schmitt, Gerhard Trube, (unknown), R. Wyler, John A. Kemp	45
10	Identification of Essential Residues Involved in the Glutamate Binding Pocket of the Group II Metabotropic Glutamate Receptor 2001 ·Molecular Pharmacology ·Pari Malherbe, Frédéric Knoflach, Clemens Broger, Serge Ohresser, Claudia Kratzeisen, Geo Adam, Heinz Stadler, John A. Kemp, Vincent Mutel	48
11	Multiple pathways for regulation of the KCl-induced [3H]-GABA release by metabotropic glutamate receptors, in primary rat cortical cultures 1998 ·Brain Research ·Hervé Schaffhauser, Frédéric Knoflach, (unknown), Zaiga Bleuel, Jayne Cartmell, (unknown), John A. Kemp, John Richards, Geo Adam, Vincent Mutel	35
12	In Vitro Binding Properties in Rat Brain of [³H]Ro 25‐6981, a Potent and Selective Antagonist of NMDA Receptors Containing NR2B Subunits 1998 ·Journal of Neurochemistry ·Vincent Mutel, (unknown), (unknown), Jürg Messer, Zaiga Bleuel, John A. Kemp, John Richards	138
13	An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones 1998 ·The Journal of Physiology ·James N.C. Kew, John A. Kemp	64
14	In vitro propagation and inducible differentiation of multipotential progenitor cells from human fetal brain 1997 ·Neuroscience ·Ruth M.E. Chalmers-Redman, Tony Priestley, John A. Kemp, Alan Fine	82
15	β‐Amyloid‐Induced Cell Toxicity: Enhancement of 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐Diphenyltetrazolium Bromide‐Dependent Cell Death 1996 ·Journal of Neurochemistry ·Cornelia Hertel, Nicole Hauser, Robert Schubenel, Bernd Seilheimer, John A. Kemp	40
16	High-Affinity and Potent, Water-Soluble 5-Amino-1,4-benzodiazepine CCKB/Gastrin Receptor Antagonists Containing a Cationic Solubilizing Group 1994 ·Journal of Medicinal Chemistry ·Graham A. Showell, (unknown), Joseph G. Neduvelil, Stephen R. Fletcher, Raymond Baker, Alan P. Watt, Alan E. Fletcher, Stephen B. Freedman, John A. Kemp	47
17	Functional expression of human D₃ dopamine receptors in differentiated neuroblastoma × glioma NG108–15 cells 1994 ·British Journal of Pharmacology ·Guy R. Seabrook, John A. Kemp, Stephen B. Freedman, Shil Patel, (unknown), George McAllister	47
18	Agonist response kinetics of N-methyl-D-aspartate receptors in neurons cultured from rat cerebral cortex and cerebellum: evidence for receptor heterogeneity. 1993 ·Molecular Pharmacology ·Tony Priestley, John A. Kemp	22
19	4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationships for antagonism at the glycine site of the NMDA receptor 1992 ·Journal of Medicinal Chemistry ·Paul D. Leeson, Robert W. Carling, Kevin W. Moore, Angela M. Moseley, (unknown), Graeme I. Stevenson, Moon Fai Chan, R. BAKER, Alan C. Foster, Sarah Grimwood, John A. Kemp, George Marshall, Karst Hoogsteen	162
20	Protection of CA1 pyramidal cell function by MK-801 following ischaemia in the gerbil 1989 ·Neuroscience Letters ·R. Gill, John A. Kemp	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact